Online inquiry

IVTScrip™ mRNA-Anti-EGFR&LGR5, MCLA-158(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11070MR)

This product GTTS-WQ11070MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets EGFR&LGR5 gene. The antibody can be applied in Colorectal Cancer (CRC) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001346897.2; NM_001277226.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956; 8549
UniProt ID Q504U8; O75473
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR&LGR5, MCLA-158(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ11070MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6082MR IVTScrip™ mRNA-Anti-CCL2, CNTO 888(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CNTO 888
GTTS-WQ6583MR IVTScrip™ mRNA-Anti-EGFR, DC-1630423(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA DC-1630423
GTTS-WQ12362MR IVTScrip™ mRNA-Anti-EGFR, N63Ab(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA N63Ab
GTTS-WQ11757MR IVTScrip™ mRNA-Anti-CTLA4, MK-1308(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MK-1308
GTTS-WQ10884MR IVTScrip™ mRNA-Anti-IL1A, MABp1(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MABp1
GTTS-WQ12941MR IVTScrip™ mRNA-Anti-MUC1, PankoMab(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PankoMab
GTTS-WQ5298MR IVTScrip™ mRNA-Anti-ALCAM, CD166 AADC(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CD166 AADC
GTTS-WQ5843MR IVTScrip™ mRNA-Anti-CD40, CHIR-12,12(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CHIR-12,12
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW